Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARA: Talazoparib, Radiotherapy and Atezolizumab in mTNBC
NCT04690855Phase 2Terminated
- Sponsor
- Mylin A. Torres
- Start
- Oct 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in triple-negative breast cancer (TNBC), sponsored by Mylin A. Torres. Primary endpoint: Objective Response Rate at 5 months. Started Oct 2021; status: terminated.
02
Drugs
talazoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04690855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690855.